Quarterly anti-vascular endothelial growth factor dosing for neovascular age-related macular degeneration: Real-world clinical outcomes

Alexander M. Rusakevich, Brenda Zhou, Tien P. Wong, Charles C. Wykoff

Research output: Contribution to journalArticle

Abstract

BACKGROUND AND OBJECTIVE: Characterize eyes managed with quarterly intravitreal anti-vascular endothelial growth factor injections for neovascular agerelated macular degeneration (nAMD). PATIENTS AND METHODS: Treatment-naïve nAMD eyes managed predominately using a treat-and-extend approach that received five or more consecutive quarterly injections from 2005 to 2017. RESULTS: One hundred fifty eyes were retrospectively identified. During quarterly dosing, a mean of 9.8 injections were given over a mean of 29 months. Ninetyone eyes (61%) had no exudative disease recurrence during quarterly dosing. Thirty-three eyes (22%) experienced exudative activity recurrence, with a mean cumulative yearly recurrence rate of 12% and a mean 6-letter loss of visual acuity (VA). Twenty-four eyes (16%) stopped quarterly treatments; nine (38%) of these subsequently experienced exudative activity recurrence with a mean 8-letter VA loss. CONCLUSION: In this real-world analysis of nAMD managed with quarterly dosing over a mean of more than 2 years' follow-up, 22% experienced disease recurrence during quarterly dosing, and 38% of eyes that stopped quarterly dosing experienced subsequent exudative disease recurrence.

Original languageEnglish (US)
Pages (from-to)E250-E256
JournalOphthalmic Surgery Lasers and Imaging Retina
Volume50
Issue number9
DOIs
StatePublished - 2019

ASJC Scopus subject areas

  • Surgery
  • Ophthalmology

Fingerprint Dive into the research topics of 'Quarterly anti-vascular endothelial growth factor dosing for neovascular age-related macular degeneration: Real-world clinical outcomes'. Together they form a unique fingerprint.

Cite this